| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2024 | 164 | 1.480 |
Why?
|
| Lymphoma, T-Cell | 7 | 2021 | 64 | 1.440 |
Why?
|
| Anemia, Aplastic | 2 | 2025 | 62 | 1.370 |
Why?
|
| Translocation, Genetic | 4 | 2024 | 350 | 1.250 |
Why?
|
| Epstein-Barr Virus Infections | 3 | 2022 | 294 | 1.240 |
Why?
|
| Myelodysplastic Syndromes | 3 | 2017 | 129 | 0.930 |
Why?
|
| Ethosuximide | 1 | 2025 | 13 | 0.900 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2018 | 156 | 0.880 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2025 | 226 | 0.880 |
Why?
|
| Burkitt Lymphoma | 2 | 2024 | 134 | 0.840 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 2 | 2022 | 50 | 0.820 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 173 | 0.800 |
Why?
|
| Herpesvirus 4, Human | 3 | 2022 | 646 | 0.780 |
Why?
|
| Hodgkin Disease | 2 | 2026 | 312 | 0.760 |
Why?
|
| Biomarkers, Tumor | 6 | 2024 | 1617 | 0.750 |
Why?
|
| Anticonvulsants | 1 | 2025 | 391 | 0.720 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2023 | 140 | 0.690 |
Why?
|
| T-Lymphocytes | 2 | 2019 | 1788 | 0.630 |
Why?
|
| Lymphoma, B-Cell | 1 | 2021 | 149 | 0.620 |
Why?
|
| Flow Cytometry | 3 | 2017 | 769 | 0.620 |
Why?
|
| Anemia | 1 | 2023 | 356 | 0.610 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2021 | 207 | 0.580 |
Why?
|
| Lymphocyte Transfusion | 1 | 2018 | 57 | 0.560 |
Why?
|
| Leukopenia | 2 | 2023 | 45 | 0.550 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2019 | 218 | 0.540 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2017 | 23 | 0.530 |
Why?
|
| Oncogene Proteins, Fusion | 4 | 2022 | 246 | 0.460 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2015 | 32 | 0.450 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2015 | 68 | 0.440 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2018 | 502 | 0.440 |
Why?
|
| Philadelphia Chromosome | 1 | 2014 | 43 | 0.430 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2014 | 44 | 0.430 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2015 | 61 | 0.430 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2014 | 53 | 0.430 |
Why?
|
| Protein-Tyrosine Kinases | 4 | 2017 | 226 | 0.420 |
Why?
|
| Panniculitis | 1 | 2013 | 18 | 0.400 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2013 | 69 | 0.390 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2022 | 152 | 0.390 |
Why?
|
| Adolescent | 15 | 2025 | 20994 | 0.390 |
Why?
|
| Myeloproliferative Disorders | 1 | 2013 | 92 | 0.370 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 91 | 0.370 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2015 | 754 | 0.370 |
Why?
|
| Chromosome Aberrations | 1 | 2015 | 577 | 0.360 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 2 | 2022 | 19 | 0.350 |
Why?
|
| Child | 14 | 2026 | 26316 | 0.320 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2012 | 210 | 0.320 |
Why?
|
| Monocytes | 1 | 2012 | 337 | 0.320 |
Why?
|
| Humans | 37 | 2026 | 131781 | 0.310 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2008 | 21 | 0.280 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2024 | 578 | 0.270 |
Why?
|
| Gene Rearrangement | 2 | 2014 | 323 | 0.270 |
Why?
|
| Bone Marrow | 3 | 2021 | 314 | 0.260 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2008 | 128 | 0.250 |
Why?
|
| Reed-Sternberg Cells | 1 | 2026 | 19 | 0.240 |
Why?
|
| Tertiary Care Centers | 2 | 2023 | 251 | 0.230 |
Why?
|
| Hyperbilirubinemia, Neonatal | 1 | 2025 | 6 | 0.230 |
Why?
|
| Female | 14 | 2025 | 71221 | 0.230 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2025 | 13 | 0.230 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 1236 | 0.230 |
Why?
|
| Diagnosis, Differential | 5 | 2024 | 1912 | 0.220 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2017 | 107 | 0.220 |
Why?
|
| Transcription Factors | 3 | 2022 | 2438 | 0.220 |
Why?
|
| Lymph Nodes | 2 | 2019 | 376 | 0.220 |
Why?
|
| Primary Myelofibrosis | 2 | 2023 | 54 | 0.220 |
Why?
|
| Cellular Senescence | 1 | 2026 | 218 | 0.210 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 2 | 2016 | 156 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2024 | 79 | 0.210 |
Why?
|
| Reticulocytes | 1 | 2023 | 30 | 0.210 |
Why?
|
| Male | 17 | 2025 | 65290 | 0.210 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2025 | 358 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2024 | 96 | 0.200 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2025 | 220 | 0.200 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2025 | 231 | 0.180 |
Why?
|
| Hemoglobins | 1 | 2023 | 314 | 0.180 |
Why?
|
| Neurodegenerative Diseases | 1 | 2025 | 288 | 0.180 |
Why?
|
| Retrospective Studies | 6 | 2023 | 17667 | 0.180 |
Why?
|
| Child, Preschool | 7 | 2025 | 15057 | 0.180 |
Why?
|
| ROC Curve | 1 | 2023 | 623 | 0.180 |
Why?
|
| Cryptococcosis | 1 | 2021 | 40 | 0.180 |
Why?
|
| Drug Eruptions | 1 | 2021 | 34 | 0.170 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 138 | 0.170 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 132 | 0.170 |
Why?
|
| Ribs | 1 | 2021 | 55 | 0.170 |
Why?
|
| Ligands | 1 | 2022 | 486 | 0.170 |
Why?
|
| Adenine | 1 | 2021 | 123 | 0.170 |
Why?
|
| Down-Regulation | 4 | 2017 | 659 | 0.160 |
Why?
|
| Mediastinal Neoplasms | 1 | 2020 | 40 | 0.160 |
Why?
|
| Autoimmune Diseases | 1 | 2023 | 275 | 0.160 |
Why?
|
| Neoplasm Staging | 2 | 2015 | 1322 | 0.160 |
Why?
|
| Sarcoma, Myeloid | 1 | 2019 | 11 | 0.160 |
Why?
|
| Piperidines | 1 | 2021 | 231 | 0.160 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 283 | 0.160 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2020 | 93 | 0.150 |
Why?
|
| Apoptosis | 2 | 2026 | 1860 | 0.150 |
Why?
|
| Testicular Neoplasms | 1 | 2020 | 123 | 0.150 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 174 | 0.150 |
Why?
|
| Central Nervous System | 1 | 2021 | 286 | 0.150 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 159 | 0.150 |
Why?
|
| Osteomyelitis | 1 | 2021 | 212 | 0.150 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 2299 | 0.150 |
Why?
|
| DNA Methylation | 2 | 2016 | 1088 | 0.150 |
Why?
|
| Prognosis | 3 | 2019 | 4953 | 0.140 |
Why?
|
| Cell Differentiation | 1 | 2026 | 1948 | 0.140 |
Why?
|
| Biopsy | 3 | 2021 | 1252 | 0.140 |
Why?
|
| Cell Proliferation | 4 | 2018 | 2483 | 0.130 |
Why?
|
| Up-Regulation | 3 | 2015 | 832 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 1280 | 0.130 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2017 | 34 | 0.130 |
Why?
|
| Image-Guided Biopsy | 1 | 2017 | 42 | 0.130 |
Why?
|
| Lung Transplantation | 1 | 2021 | 350 | 0.130 |
Why?
|
| Infant | 6 | 2025 | 13324 | 0.120 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2016 | 30 | 0.120 |
Why?
|
| Megakaryocytes | 1 | 2016 | 42 | 0.120 |
Why?
|
| Protein Kinases | 1 | 2017 | 322 | 0.120 |
Why?
|
| Syndrome | 1 | 2018 | 1170 | 0.120 |
Why?
|
| MicroRNAs | 2 | 2013 | 895 | 0.120 |
Why?
|
| Sumoylation | 1 | 2015 | 41 | 0.110 |
Why?
|
| Receptors, Somatomedin | 1 | 2015 | 21 | 0.110 |
Why?
|
| Monosomy | 1 | 2015 | 25 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 2 | 2015 | 1219 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2025 | 5297 | 0.110 |
Why?
|
| Thrombocytopenia | 1 | 2016 | 222 | 0.110 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 1610 | 0.110 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2015 | 112 | 0.110 |
Why?
|
| Immunophenotyping | 1 | 2015 | 336 | 0.100 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2014 | 22 | 0.100 |
Why?
|
| DNA, Neoplasm | 1 | 2015 | 287 | 0.100 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2013 | 15 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2122 | 0.100 |
Why?
|
| Cytokines | 2 | 2021 | 1348 | 0.100 |
Why?
|
| Axilla | 1 | 2013 | 43 | 0.100 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2013 | 31 | 0.100 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2015 | 356 | 0.100 |
Why?
|
| Genomics | 1 | 2021 | 1626 | 0.100 |
Why?
|
| Leukemia | 1 | 2016 | 375 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2026 | 2004 | 0.100 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2013 | 91 | 0.100 |
Why?
|
| Lung Neoplasms | 2 | 2013 | 1542 | 0.100 |
Why?
|
| Fatal Outcome | 1 | 2013 | 364 | 0.090 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 2148 | 0.090 |
Why?
|
| RNA, Neoplasm | 1 | 2012 | 127 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2015 | 611 | 0.090 |
Why?
|
| Liver | 1 | 2019 | 1799 | 0.090 |
Why?
|
| Hematologic Neoplasms | 1 | 2015 | 314 | 0.090 |
Why?
|
| Recurrence | 1 | 2015 | 1483 | 0.080 |
Why?
|
| STAT3 Transcription Factor | 1 | 2013 | 233 | 0.080 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2015 | 550 | 0.080 |
Why?
|
| Prevalence | 1 | 2017 | 2695 | 0.080 |
Why?
|
| Young Adult | 3 | 2025 | 10102 | 0.070 |
Why?
|
| Cell Survival | 3 | 2017 | 854 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2021 | 3416 | 0.070 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 327 | 0.070 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2008 | 39 | 0.070 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2008 | 63 | 0.070 |
Why?
|
| Age Factors | 1 | 2014 | 2872 | 0.070 |
Why?
|
| Heart Transplantation | 1 | 2013 | 833 | 0.060 |
Why?
|
| Cell Line, Tumor | 4 | 2017 | 3694 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2015 | 12997 | 0.060 |
Why?
|
| Hemolysis | 1 | 2025 | 86 | 0.060 |
Why?
|
| Phenotype | 1 | 2015 | 4528 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 618 | 0.050 |
Why?
|
| Time Factors | 1 | 2015 | 6279 | 0.050 |
Why?
|
| Middle Aged | 4 | 2025 | 28897 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2025 | 353 | 0.050 |
Why?
|
| RNA-Binding Proteins | 1 | 2008 | 548 | 0.050 |
Why?
|
| Mice | 5 | 2021 | 18479 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2017 | 1571 | 0.050 |
Why?
|
| Neoplasms | 1 | 2017 | 2963 | 0.050 |
Why?
|
| Perforin | 1 | 2021 | 26 | 0.040 |
Why?
|
| Mutation | 3 | 2021 | 6194 | 0.040 |
Why?
|
| Acute Disease | 1 | 2024 | 1153 | 0.040 |
Why?
|
| Cytogenetic Analysis | 1 | 2020 | 79 | 0.040 |
Why?
|
| Algorithms | 2 | 2021 | 1685 | 0.040 |
Why?
|
| Cell Movement | 2 | 2015 | 886 | 0.040 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 180 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 199 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2021 | 298 | 0.040 |
Why?
|
| Animals | 5 | 2021 | 34402 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2026 | 1835 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 344 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 313 | 0.040 |
Why?
|
| Signal Transduction | 3 | 2017 | 4682 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2022 | 781 | 0.030 |
Why?
|
| Nerve Growth Factor | 1 | 2017 | 22 | 0.030 |
Why?
|
| Disease Management | 1 | 2021 | 565 | 0.030 |
Why?
|
| Chondrosarcoma | 1 | 2017 | 13 | 0.030 |
Why?
|
| Rhabdoid Tumor | 1 | 2017 | 48 | 0.030 |
Why?
|
| Reticulin | 1 | 2016 | 8 | 0.030 |
Why?
|
| Bone Marrow Examination | 1 | 2016 | 15 | 0.030 |
Why?
|
| Integrin beta3 | 1 | 2016 | 28 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2017 | 579 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2016 | 136 | 0.030 |
Why?
|
| Sarcoma, Ewing | 1 | 2017 | 117 | 0.030 |
Why?
|
| Jurkat Cells | 1 | 2015 | 84 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2016 | 205 | 0.030 |
Why?
|
| Protein Stability | 1 | 2015 | 166 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2017 | 664 | 0.030 |
Why?
|
| 3T3 Cells | 1 | 2015 | 121 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2017 | 300 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2015 | 93 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2016 | 274 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2025 | 6509 | 0.030 |
Why?
|
| Osteosarcoma | 1 | 2017 | 265 | 0.030 |
Why?
|
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2013 | 6 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 999 | 0.030 |
Why?
|
| Leukocytosis | 1 | 2014 | 46 | 0.030 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2014 | 66 | 0.030 |
Why?
|
| Aged | 3 | 2021 | 21263 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 1522 | 0.030 |
Why?
|
| Karyotyping | 1 | 2014 | 313 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 2353 | 0.020 |
Why?
|
| Imines | 1 | 2013 | 10 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2014 | 144 | 0.020 |
Why?
|
| Protein Binding | 1 | 2017 | 1711 | 0.020 |
Why?
|
| Adult | 2 | 2025 | 31710 | 0.020 |
Why?
|
| Tyrosine | 1 | 2013 | 148 | 0.020 |
Why?
|
| Neprilysin | 1 | 2012 | 20 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2013 | 312 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2021 | 5122 | 0.020 |
Why?
|
| Pneumonectomy | 1 | 2013 | 151 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2025 | 8597 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2012 | 62 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2014 | 364 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 295 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 530 | 0.020 |
Why?
|
| Biomarkers | 1 | 2021 | 3411 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2012 | 240 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 766 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2012 | 595 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2013 | 489 | 0.020 |
Why?
|
| Transfection | 1 | 2012 | 960 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2013 | 466 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2993 | 0.020 |
Why?
|
| Cell Line | 1 | 2015 | 2606 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 329 | 0.020 |
Why?
|
| Binding Sites | 1 | 2012 | 1202 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2015 | 2570 | 0.020 |
Why?
|
| Base Sequence | 1 | 2012 | 2783 | 0.020 |
Why?
|
| Pediatrics | 1 | 2017 | 1232 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2015 | 3862 | 0.020 |
Why?
|